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for moderate to severe 
depression in adolescents?
Treat with vigilance
Based on the available evidence, I’m 
confi dent in my decision to use SSRIs 
to treat depressed adolescents. But the 
FDA black box warning often leaves me 
with a sense of apprehension as I write 
the prescription. I consider this a healthy 
reminder that depression in adolescents is 
no small matter, and its treatment shouldn’t 
be taken lightly. 
 In my practice, patient and family 
education always accompany the use of 
SSRIs, as does weekly follow-up in the 
beginning. Of the many patient education 
resources available on the Internet, my 
favorite Web sites include: 
 • www.familydoctor.org, 
 •  www.aacap.org (Facts for Families),
 •  www.kidshealth.org (features pages 
for both parents and teenagers), and 
 •  www.medlineplus.gov (handouts in 
English and Spanish and interactive 
tutorials). 
 Finally, no adolescent leaves my offi ce 
without suicide precautions and phone 
numbers of local and national suicide 
prevention hotlines (www.suicidehotlines.
com).
Jason Crawford, MD, MPH
University of Nevada School of Medicine, Reno 
Clinical commentary
Selective serotonin-reuptake inhibitors 
(SSRIs) appear to be the safest, given 
current data. 
 Major safety concerns—prompting a 
US Food and Drug administration (FDA) 
black box label warning—have been 
raised about increased risk of suicidality 
(ideation, behavior, and attempts) among 
adolescents receiving antidepressant 
therapy. Studies indicate that SSRIs 
and venlafaxine increase the absolute 
risk of suicidality by 1% to 2% compared 
with placebo. However, no suicides 
occurred during any study. On detailed 
subanalysis, each SSRI was as safe 
as placebo, and only venlafaxine 
demonstrated a statistically signifi cant 
increase in risk of suicidality (strength 
of recommendation [SOR]: A, meta-
analysis).
 Information about the safety of tricyclic 
antidepressants in young people is limited 
because adverse effects have not been 
systematically reported in trials (SOR: A, 
meta-analysis).
 (For information on the effi cacy of 
antidepressants in adolescents, see the 
Clinical Inquiry on page 330.)
Evidence-based answer
❚ Evidence summary
In 2003, the United Kingdom’s Expert 
Working Group of the Committee on 
Safety of Medicines (CSM) and the FDA 
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conducted a review and meta-analysis, 
respectively, of the newer antidepressants 
used in children and adolescents.1,2 Based 
on these studies, the FDA mandated that 
all antidepressant labels carry a black 
box warning about the increased risk 
of suicidal thinking and behavior (sui-
cidality) among adolescents taking the 
medications. 
No suicides, but a two-fold 
increase in suicidality
A recent study that incorporated the 
FDA meta-analysis analyzed data from 
4582 patients. Although no completed 
suicides were reported in any trial, the 
drug-treated groups had a two-fold in-
crease in suicidality compared with pla-
cebo groups (4% vs 2%; number needed 
to harm [NNH]=50).3 A recent Cochrane 
review confi rmed the increase in absolute 
risk (1.8; 95% confi dence interval [CI], 
1.19-2.72).4
Two subsequent analyses estimat-
ed the difference in risk to be 1.6-fold 
with a 95% CI of 1.0-2.7 (3% vs 2%; 
NNH=112).5,6 The lower estimated risk 
results largely from a statistical reframing 
rather than any major difference in data 
analyzed. The analyses used a random-
effects model instead of a fi xed-effects 
model to calculate suicidality, assuming 
heterogeneity in the drugs used, trial de-
signs, and outcome measures.3,6 All of the 
analyzed trials excluded patients at high 
risk for suicide, defi ned uniquely in the 
exclusion criteria for each trial.
The TABLE summarizes the increased 
risk of suicidality for each drug. Nota-
bly, venlafaxine had the greatest—and 
only statistically signifi cant—increased 
risk, mostly because of suicidal ideation 
(7 of 9 events in 182 treated patients vs 
none in 179 placebo patients).6 (For a de-
tailed look at the risk of suicidal ideation, 
suicidal behavior, or suicide attempt, 
see TABLE W1, available online at www.
jfponline.com.) 
Data on tricyclics in adolescents 
are scarce
Evidence concerning the safety of tri-
cyclic antidepressants in adolescents is 
limited because adverse effects have not 
been systematically reported. A 2002 Co-
chrane meta-analysis found a statistically 
signifi cant increase in rates of vertigo, 
orthostatic hypotension, tremor, and dry 
mouth among children and adolescents 
taking tricyclic antidepressants compared 
with placebo. The drugs are modestly ef-
fective in treating depression in adoles-
cents; concerns about side effects and 
safety, however, have limited their use.7
Recommendations 
The FDA encourages patients taking 
antidepressants and their families to be 
alert for signs of impulsive behavior or 
suicidal tendencies and to have a safety 
plan. The FDA, American Academy of 
Child and Adolescent Psychiatry, and the 
Society for Adolescent Medicine endorse 
close follow-up with periodic objective 
assessment.8-10
The Society for Adolescent Medicine 
explicitly directs clinicians to consider 
the FDA black box warning in the con-
text of the need to treat major depres-
sive disorder in adolescents and endorses 
pharmacotherapy for appropriately se-
lected patients.10 Similarly, the American 
Venlafaxine 
had the only 
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of suicidality—
mostly because of 
suicidal ideation
Risk of suicidality among young people 
taking antidepressants—
Pooled results of 2 meta-analyses1,4
TABLE 
DRUG META-ANALYSIS OR* (95% CI)
Citalopram, Hammad3 1.37 (0.53-3.50)
escitalopram  Dubicka6 1.21 (0.60-2.45)
Fluoxetine  Hammad  1.53 (0.74-3.16)
 Dubicka 1.36 (0.65-2.88)
Paroxetine  Hammad 2.15 (0.71-6.52)
 Dubicka 1.53 (0.61-3.84)
Sertraline  Hammad 2.16 (0.48-9.62)
 Dubicka 2.47 (0.47-12.9)
Venlafaxine  Hammad 8.84 (1.12-69.51)
 Dubicka 14.83 (1.93-114.0)
*Includes suicidal ideation, behavior, and attempts.
CI, confi dence interval; OR, odds ratio.
College of Neuropsychopharmacology 
argues that the risk-to-benefi t ratio fa-
vors drug treatment for moderate to se-
vere adolescent depression.11 ■
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